Menu
Recruiting NCT07275190

The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome

No phase Interventional EGPA - Eosinophilic Granulomatosis With Polyangiitis HES - Hypereosinophilic Syndrome

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Blood draw for the laboratory assessment.
Who it may be relevant to
Registry conditions: EGPA - Eosinophilic Granulomatosis With Polyangiitis, HES - Hypereosinophilic Syndrome. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The purpose of this study is to collect clinical, laboratory, and instrumental data from patients with eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome, which will then be analyzed using artificial intelligence techniques with the aim of identifying characteristics that differentiate the two diseases and can predict the response to the treatment plan.

Interventions

  • Procedure Blood draw for the laboratory assessment
    Blood draw for the laboratory assessment

Primary outcome measures

  • characteristics that are different between HES and EGPA [Time frame: 18months]

Eligibility criteria

Inclusion criteria

  • 18 years of age or over
  • A diagnosis of EGPA or HES
  • Willing and able to give informed written consent, or willing to give permission for a nominated friend or relative to provide written informed assent if they are unable to do so because of physical disabilities

Exclusion criteria

  • Lack of a confirmed diagnosis of EGPA or HES.
  • Other causes of eosinophilia

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Parallel assignment
Masking
Open label
Primary purpose
Other

Study locations

Italy · 1 center
  • Fondazione IRCCS Policlinico San Matteo, SC Reumatologia — Pavia

Identifiers

NCT: NCT07275190 · AI_EH_resub

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗